SMT201600458B - Composizioni comprendenti buprenorfina - Google Patents

Composizioni comprendenti buprenorfina

Info

Publication number
SMT201600458B
SMT201600458B SM201600458T SM201600458T SMT201600458B SM T201600458 B SMT201600458 B SM T201600458B SM 201600458 T SM201600458 T SM 201600458T SM 201600458 T SM201600458 T SM 201600458T SM T201600458 B SMT201600458 B SM T201600458B
Authority
SM
San Marino
Prior art keywords
compositions including
including buprenorphine
buprenorphine
compositions
Prior art date
Application number
SM201600458T
Other languages
English (en)
Inventor
Richard L Norton
Mingxing Zhou
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of SMT201600458B publication Critical patent/SMT201600458B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages
    • B65B55/04—Sterilising wrappers or receptacles prior to, or during, packaging
    • B65B55/08—Sterilising wrappers or receptacles prior to, or during, packaging by irradiation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages
    • B65B55/12—Sterilising contents prior to, or during, packaging
    • B65B55/16—Sterilising contents prior to, or during, packaging by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM201600458T 2010-06-08 2016-12-19 Composizioni comprendenti buprenorfina SMT201600458B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009546.1A GB2481017B (en) 2010-06-08 2010-06-08 Microparticle buprenorphine suspension
PCT/GB2011/051058 WO2011154725A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (1)

Publication Number Publication Date
SMT201600458B true SMT201600458B (it) 2017-03-08

Family

ID=42471304

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20160458T SMT201600458T1 (it) 2010-06-08 2011-06-06 Composizioni comprendenti buprenorfina
SM201600458T SMT201600458B (it) 2010-06-08 2016-12-19 Composizioni comprendenti buprenorfina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20160458T SMT201600458T1 (it) 2010-06-08 2011-06-06 Composizioni comprendenti buprenorfina

Country Status (20)

Country Link
US (2) US9295645B2 (it)
EP (2) EP2579875B1 (it)
CN (1) CN103068387B (it)
AU (2) AU2011263479B2 (it)
BR (1) BR112012031288A2 (it)
CA (1) CA2802005A1 (it)
CY (1) CY1118307T1 (it)
DK (2) DK3146960T3 (it)
ES (1) ES2604703T3 (it)
GB (2) GB2513060B (it)
HR (1) HRP20161533T1 (it)
HU (1) HUE032481T2 (it)
LT (1) LT2579875T (it)
PL (1) PL2579875T3 (it)
PT (1) PT2579875T (it)
RS (1) RS55517B1 (it)
RU (1) RU2608912C2 (it)
SI (1) SI2579875T1 (it)
SM (2) SMT201600458T1 (it)
WO (1) WO2011154725A2 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
MX342675B (es) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Formulaciones estables para inyeccion parenteral de farmacos de peptido.
PL2773331T3 (pl) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
PL3512518T3 (pl) 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
ES2982668T3 (es) 2017-06-02 2024-10-17 Xeris Pharmaceuticals Inc Formulaciones de fármacos de moléculas pequeñas resistentes a la precipitación
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN112236142A (zh) 2018-01-22 2021-01-15 逸达生物科技股份有限公司 用于缓释递送丁丙诺啡的药物组合物
EP3790881A4 (en) 2018-05-11 2022-03-09 Alar Pharmaceuticals Inc. LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES
CN116669717A (zh) * 2020-08-17 2023-08-29 美国人福制药公司 长效原位成型/胶凝组合物

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB784659A (en) * 1954-11-26 1957-10-16 Upjohn Co Therapeutic compositions and aqueous suspensions thereof
GB806876A (en) 1956-02-16 1959-01-07 Wellcome Found Improvements in and relating to disposable hypodermic injection devices
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
GB887872A (en) 1958-06-25 1962-01-24 Upjohn Co Improvements in or relating to pharmaceutical preparations
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
US4534974A (en) 1984-07-31 1985-08-13 Carter-Wallace, Inc. Pharmaceutical compositions with codeine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4599354A (en) * 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
JP3219096B2 (ja) 1990-05-10 2001-10-15 ニコメド ファーマ エイエス ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
CA2103725C (en) 1991-02-18 2002-06-04 Reginald Morton Taylor Composition for use in transdermal administration
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
US5346803A (en) * 1993-09-15 1994-09-13 Shin-Etsu Chemical Co., Ltd. Photoresist composition comprising a copolymer having a di-t-butyl fumarate
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
DK0754032T3 (da) 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
WO1996039995A1 (en) 1995-06-07 1996-12-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
HU225819B1 (en) 1996-06-17 2007-10-29 Janssen Pharmaceutica Nv Biconvex rapidly disintegrating dosage forms
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
IT1292396B1 (it) 1997-06-23 1999-02-08 Lisapharma Spa Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE19923551A1 (de) 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
JP4913298B2 (ja) * 1999-08-27 2012-04-11 ブルックウッド ファーマシューティカルズ，インコーポレイティド 注射可能なブプレノルフィン微粒子組成物及びその使用
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003041684A2 (en) 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
NZ535270A (en) 2002-03-12 2006-11-30 Univ Montreal Composition having gelling properties for the sustained delivery of bioactive substances
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
RU2310450C2 (ru) 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE60325511D1 (de) 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
CA2515146C (en) * 2003-02-04 2011-12-06 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
JP5229768B2 (ja) 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
FI20045223A7 (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
WO2005037949A2 (en) 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP2286791B1 (en) 2003-12-30 2014-03-26 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
EP1804751A2 (en) 2004-10-04 2007-07-11 QLT USA, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
PL1824460T3 (pl) 2004-11-10 2015-09-30 Tolmar Therapeutics Inc Stabilizowany polimerowy układ dostarczania
GB2420976B (en) 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
US20090092650A1 (en) 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
WO2006063430A1 (en) 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US9415034B2 (en) 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
EP2548581A3 (en) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US9017709B2 (en) 2005-08-11 2015-04-28 Promedon S.A. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1959935A2 (en) 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
EP1954275A2 (en) 2005-11-21 2008-08-13 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
WO2007103185A2 (en) * 2006-03-01 2007-09-13 University Of Tennessee Research Foundation Sustained release dosage forms of analagesic medications
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CN105168186A (zh) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 非粘膜粘着性膜剂型
US20100015195A1 (en) 2006-10-05 2010-01-21 Rajesh Jain Injectable depot compositions and it's process of preparation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
CA2666341C (en) 2006-10-11 2012-01-03 Qlt Usa, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US9187593B2 (en) 2007-02-15 2015-11-17 Tolmar Therapeutics, Inc. Low burst polymers and methods to produce polymer
BRPI0807290A2 (pt) 2007-03-02 2016-10-11 Teika Pharmaceutical Co Ltd "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
WO2009032246A2 (en) 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
FR2926996B1 (fr) 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
JP5737949B2 (ja) 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
EP2254559B1 (en) 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
JP2011515495A (ja) 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
US9308162B2 (en) 2008-06-03 2016-04-12 Tolmar Therapeutics, Inc. Biocompatible oligomer-polymer compositions
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
CN102458358A (zh) 2009-04-23 2012-05-16 伦敦制药有限公司 包含中性油的舌下药学组合物
AR076540A1 (es) 2009-05-01 2011-06-22 Eurand Inc Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
WO2011063156A2 (en) 2009-11-18 2011-05-26 Nektar Therapeutics Acid salt forms of polymer-drug conjugates and alkoxylation methods
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
WO2011115871A1 (en) 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
ES2897976T3 (es) 2010-05-31 2022-03-03 Farm Rovi Lab Sa Composiciones para implantes in situ biodegradables inyectables
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
BR112013012156A2 (pt) 2010-11-17 2017-12-05 Hexal Ag sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
BR112013013123A2 (pt) 2010-11-26 2018-06-19 Univ Johannesburg Witwatersrand dispositivo de entrega de fármaco
US20140363487A1 (en) 2011-12-12 2014-12-11 Purdue Pharma L.P. Transdermal delivery system comprising buprenorphine
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
EP3045162B1 (en) 2012-07-26 2021-07-07 Camurus AB Opioid formulations
US20140134261A1 (en) 2012-08-21 2014-05-15 Trinity Laboratories, Inc. Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
RU2513514C1 (ru) 2012-11-23 2014-04-20 Общество с ограниченной ответственностью "НПК "Трифарма" Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
IN2013MU03658A (it) 2013-11-21 2015-09-25 Akanksha Bindeshwari Prasad Yadav
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations

Also Published As

Publication number Publication date
CA2802005A1 (en) 2011-12-15
RU2012157247A (ru) 2014-07-20
CN103068387A (zh) 2013-04-24
AU2011263479A1 (en) 2013-01-10
EP3146960B1 (en) 2019-02-20
RU2608912C2 (ru) 2017-01-26
GB2481017B (en) 2015-01-07
CN103068387B (zh) 2016-10-12
AU2016200509B2 (en) 2017-07-20
LT2579875T (lt) 2017-01-10
HUE032481T2 (en) 2017-09-28
GB201009546D0 (en) 2010-07-21
SI2579875T1 (sl) 2017-02-28
US9295645B2 (en) 2016-03-29
EP2579875A2 (en) 2013-04-17
US10172849B2 (en) 2019-01-08
EP2579875B1 (en) 2016-11-09
DK2579875T3 (en) 2016-12-12
SMT201600458T1 (it) 2017-03-08
PL2579875T3 (pl) 2017-08-31
GB2513060B (en) 2015-01-07
RS55517B1 (sr) 2017-05-31
WO2011154725A2 (en) 2011-12-15
CY1118307T1 (el) 2017-06-28
BR112012031288A2 (pt) 2016-11-01
US20130202658A1 (en) 2013-08-08
HRP20161533T1 (hr) 2017-02-10
GB2513060A (en) 2014-10-15
PT2579875T (pt) 2016-11-29
ES2604703T3 (es) 2017-03-08
GB201413135D0 (en) 2014-09-10
US20160184296A1 (en) 2016-06-30
AU2016200509A1 (en) 2016-02-18
EP3146960A1 (en) 2017-03-29
WO2011154725A3 (en) 2012-06-28
DK3146960T3 (en) 2019-04-01
AU2011263479B2 (en) 2015-10-29
GB2481017A (en) 2011-12-14

Similar Documents

Publication Publication Date Title
SMT201600458B (it) Composizioni comprendenti buprenorfina
DK2640893T4 (da) Sammensætninger
LT3246021T (lt) Apiksabano kompozicijos
BR112012031667A2 (pt) composição
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
EP2575450A4 (en) CYCLOPROPENZUSAMMENSETZUNGEN
BR112013017183A2 (pt) composições de bepostatina
LT2791160T (lt) Modifikuotos mrnr sudėtys
BR112012032683A2 (pt) composição
PT2621277T (pt) Composições fungicidas
EP2609148A4 (en) PHTHALIC ACID-FREE SOFT MAKER
EP2594729A4 (en) VERBUNDBOHRSPITZE
LT3158991T (lt) Bendamustino kompozicijos
EP2522643A4 (en) CONCRETE COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
EP2636704A4 (en) FILM FORMING COMPOSITION
BR112013014204A2 (pt) composições de sucops espumantes
EP2628769A4 (en) FILM FORMING COMPOSITION
BR112012032980A2 (pt) composição
EP2548563A4 (en) ANTIALLERGIC COMPOSITION
EP2531023A4 (en) IMPROVED FORMULATION
EP2635269A4 (en) COMBINATION COMPOSITION
EP2624836A4 (en) BEPOTASTIN COMPOSITION
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
BR112013014673A2 (pt) composições orais